On March 18, 2026, LeonaBio, Inc. held a special meeting of stockholders where significant corporate actions were approved. The stockholders voted to approve the 2026 Equity Incentive Plan, which aims to attract and retain top talent by providing various forms of equity compensation, including stock options and performance awards. This plan replaces the previous 2020 Equity Incentive Plan, which has now been terminated for future grants. The new plan allows for the issuance of up to 5,700,000 shares, with additional shares becoming available through the cancellation of unexercised options from the prior plan.

In addition to the equity incentive plan, stockholders also approved an amendment to the company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 90 million to 400 million. This increase is intended to provide the company with greater flexibility in its capital structure and to support future financing needs. The total number of authorized shares of capital stock will rise from 190 million to 500 million, while the number of authorized preferred shares remains unchanged.

The approval of these measures reflects the company's strategic outlook to enhance its operational capabilities and ensure it can effectively compete in the biotechnology sector. The board of directors emphasized that these changes are essential for the company's growth and to align the interests of employees and shareholders. The meeting saw a quorum with approximately 79.63% of the total shares entitled to vote present or represented by proxy, indicating strong shareholder engagement in corporate governance matters.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.